What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alopecia Areata(AA)
- Main trialPhase 1
- “This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)”In the company’s words, NCT07049328 on ClinicalTrials.gov
Other drugs for Alopecia Areata(AA)
- RitlecitinibPfizer · Phase 3
- DeuruxolitinibSun Pharmaceutical Industries, Inc. · Concert Pharmaceuticals · Phase 3
- UpadacitinibAbbVie · Phase 3
- ALD-102Aldena Therapeutics · Phase 1/2
- SYHX1901CSPC · Phase 2
- LAD603Almirall, S.A. · Phase 2
Coming up1
- 16 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 16 Jul 2027 | HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026